# FDA 483 - MedImmune U.K. Limited - March 15, 2024

Source: https://www.keypedia.com/records/483/medimmune-uk-limited/7412f120-467e-4587-9e8c-bfae5fcb83d0

> FDA 483 for MedImmune U.K. Limited on March 15, 2024. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: MedImmune U.K. Limited
- Inspection Date: 2024-03-15
- Product Type: biologics
- Office Name: International Compliance Team
- Summary: An FDA inspection of MedImmune U.K. Limited, a biologic vaccine drug substance manufacturer in Liverpool, revealed significant deficiencies in quality control and documentation practices. Observations included inadequate deviation reporting and impact assessment, insufficient data for positive control qualification, and incomplete investigations into action level excursions. Additionally, batch records were found to be inadequately designed to capture critical verification steps for vaccine production.

## Related Documents

- [483 - Unknown Date](https://www.keypedia.com/records/483/medimmune-uk-limited/90c6cc7c-2aae-4fd3-a61c-da354f0af2aa)
- [483 - 2022-06-14](https://www.keypedia.com/records/483/medimmune-uk-limited/da74227b-d0d4-489c-8236-f2dbd359dfe9)

## Related Officers

- [Anissa M Chouhy](https://www.keypedia.com/people/anissa-m-chouhy/1295e9fa-c86d-450a-89d2-624c4a822850)
- [Gene D. Arcy](https://www.keypedia.com/people/gene-d-arcy/a2def947-65fb-4056-84e2-1f89cf944cf0)
- [investigator](https://www.keypedia.com/people/brantley-s-collins/c806aac1-3d89-4427-8aeb-6d9db6dfc2f4)

Company: https://www.keypedia.com/companies/medimmune-uk-limited/fbddd1ed-5a0c-4c65-a48e-bb2af79482ed

Office: https://www.keypedia.com/offices/international-compliance-team/f0ce0d89-bf39-46c6-8c42-28138d161321